Eloxx Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Eloxx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule product candidates designed to modulate the ribosome and promote the readthrough of premature stop codons induced by nonsense mutations (NMs). This mechanism enables the production of functional, full-length proteins, offering a targeted therapeutic approach to rare and ultra-rare genetic diseases. The company's lead investigational drug candidate is exaluren (also known as ELX-02), which is being developed for genetically defined patient subsets with rare kidney diseases, specifically Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) caused by nonsense mutations. Additionally, through a strategic collaboration with Almirall, S.A., the company is advancing ZKN-013 for the treatment of rare dermatological diseases, such as recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB).
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead investigational drug candidate, exaluren (ELX-02), for rare kidney diseases. This includes initiating a Phase 2b clinical trial in nonsense mutation Alport Syndrome (NMAS) and preparing for a Phase 2 trial in nonsense mutation Autosomal Dominant Polycystic Kidney Disease (nmADPKD).
Expected impact: Establish clinical proof of efficacy and safety to support regulatory filings and potential commercialization in high-unmet-need rare kidney indications.
Executing corporate restructurings, including a 1-for-11 reverse stock split on May 29, 2026, reducing authorized common shares to 100 million, and completing a $66.0 million public offering to regain compliance and uplist to the Nasdaq Capital Market.
Expected impact: Regain Nasdaq compliance, improve stock liquidity, and secure the necessary capital to fund operations and clinical trials.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High
Terms: Eloxx received a $6.0 million upfront payment and a $3.0 million milestone in 2024. Eloxx remains eligible to receive up to approximately $470.0 million in potential development, regulatory, and sales milestones, plus tiered royalties on future global sales.
Medium
Terms: Under the February 2026 CFF Omnibus Agreement, upon completion of certain milestones and a one-time payment, Eloxx reduced its royalty obligations to CFF to less than 1% of net sales of exaluren for any disease amenable to read-through treatment, terminating the 2021 CFF Award Agreement.